发给老马备查:% i4 d) t3 M2 V+ K* g
滴水察海(69304838) 15:23:237 y, P/ N$ ?; D; E% u) {5 x' \
老马,我看到培美和S-1都提到TS低表达,而鳞多半不是低表达,是不是S-1不靠谱/ @' q4 i# C; i0 T% Y/ b' K, J6 l6 F' G
吉非替尼和S-1连用的依据. O& u; a Z @2 C
Gefitinib induced down-regulation of thymidylate synthase and E2F-1 in gefitinib-resistant NSCLC cells with MET amplification but not in those harboring the T790M mutation of EGFR. The combination of 5-fluorouracil and gefitinib synergistically inhibited the proliferation of cells with MET amplification, but not that of those with the T790M mutation of EGFR, in vitro.6 ^- ~) K, a& a; D: `
是不是说因C-MET引起的耐药中,吉非替尼会引导TS低表达
* N" b9 F+ G9 P6 J$ ?# k7 z' U6 M这样是不是推理出,耐药后,可以用S-1和培美了?
/ c* l6 o" [9 ~, B结论:- C# \7 f5 z$ ]. n U
如果是T790M突变引起的耐药,则2992有效,如果是C-MET扩增引起的突变,则除了184,还可以特+S1联用,而且可能可以用培美。 |